Mural Oncology Plc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Mural Oncology Plc's ROI in the third quarter of 2025?
Mural Oncology Plc recorded a cumulative net loss of $-119 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -129.99%.

Within the Healthcare sector 669 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3276 to 3627.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Investment Change TTM	-59.44 %	-33.47 %	25.91 %	190.31 %	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	55	59	109	143	178
Return On Investment (TTM)	-129.99 %	-120.22 %	-81.61 %	-66.41 %	-68.07 %
MURA's Overall Ranking	# 3627	# 3276	# 3112	# 2876	# 3027
Seq. Investment Change TTM	-25.15 %	-23.59 %	-17.22 %	-14.33 %	22.78 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-119	-147	-131	-129	-154

MURA Company Profile >> Back to MURA Roi Comparisons >> See Annual MURA Return On Investment

Return On Investment MURA's Ranking
Within:	No.
Industry	# 312
Sector	# 670
Overall	# 3627

Return On Investment Statistics
High	Average	Low
-66.41 %	-109.29 %	-146.71 %
(Dec 31 2024)		(Jun 30 2024)

Financial Statements
Mural Oncology Plc's III. Quarter Investments	$ 55 Millions	MURA's Balance sheet
Mural Oncology Plc's III. Quarter Income	$ -4 Millions	Quarterly MURA's Income Statement
MURA's Income by Division		See MURA's Income by Division

MURA Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(FY 2012) (Dec. 29, 2012)
Total Investments in Millions	143	273	0	0	0
Y / Y Investment Growth	-47.49 %	-	-	-	-
Net Income in Millions	-129	-207	964	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-89.75 %	-76.06 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MURA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MURA's Competitors
Subscribers only: Roi for Mural Oncology Plc's Suppliers
Subscribers only: Return On Investment for MURA's Customers

Other Ratios
MURA's Roa	MURA's Inventory Turnover Ratio	MURA's Growth Rates	MURA's Dividend Statistics
	MURA's Profitability Ratios	MURA's Asset Turnover Ratio	MURA's Dividend Growth
MURA's Roe	MURA's Valuation Ratios	MURA's Financial Strength Ratios	MURA's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector

ROI

Date modified: 2026-08-29T17:49:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.